Trials / Completed
CompletedNCT00696826
A Study of MK0431 in Patients WIth Hepatic Insufficiency (0431-017)(COMPLETED)
An Open-Label, Single Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK0431
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A study to compare the plasma concentrations of MK0431 at different times in patients with hepatic insufficiency vs healthy control subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | sitagliptin phosphate | sitagliptin phosphate 100 mg MK0431 (2 x 50 mg tablets) taken orally after overnight fast; Duration of Treatment: 5 Weeks |
Timeline
- Start date
- 2004-04-01
- Primary completion
- 2004-05-01
- Completion
- 2004-05-01
- First posted
- 2008-06-13
- Last updated
- 2015-08-19
Source: ClinicalTrials.gov record NCT00696826. Inclusion in this directory is not an endorsement.